GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
N

Nuformix NFX.L · GBp

Health Care · LSE · 🇬🇧 United Kingdom

Compare

0.11p

0.00%

Close of 9 Nov 2026, in pence

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Nuformix

Its shares trade on LSE under the ticker NFX.L. It has been listed since 17 December 2015. In the fiscal year to 31 March 2021, it reported revenue of £50,000 and a net loss of £1.1m. At that date it held total assets of £5.0m and shareholders' equity of £4.7m.

Nuformix Plc is a pharmaceutical development company, which targets unmet medical needs in fibrosis and oncology via drug repurposing. The firm is engaged in targeting unmet medical needs in fibrosis and oncology via drug repurposing. Its clinical pipeline includes NXP001, NXP002, and NXP004. NXP002 is its pre-clinical lead asset and a potential inhaled treatment for idiopathic pulmonary fibrosis (IPF) and possibly other fibrosing interstitial lung diseases (ILDs). NXP001 is a form of the drug aprepitant that is marketed as a product in the oncology supportive care setting (chemotherapy-induced nausea and vomiting). NXP004 is a form of Olaparib, which is used for the treatment of adults with advanced ovarian cancer and deleterious or suspected deleterious germline BRCA mutation.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
17 Dec 2015
Employees
2

Leadership

Pay as last reported

  • Roger J. JonesSecretary, since 2019
  • Alastair J. Riddell, PhD, MDExecutive Chairman, since 2022
  • Madeleine KennedyNon-Executive Director, since 2020
  • Julian Gilbert, PhDNon-Executive Director, since 2020

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Nuformix PLC targets unmet medical needs in fibrosis and oncology through drug repurposing.
  • NXP002 is a pre-clinical lead asset for inhaled treatment of idiopathic pulmonary fibrosis (IPF).
  • NXP001 is a marketed product for chemotherapy-induced nausea and vomiting in oncology care.

Weaknesses

  • Nuformix PLC has only two employees, limiting operational capacity.
  • The company is listed on the London Stock Exchange since 2015 with minimal market presence.
  • NXP004 is limited to advanced ovarian cancer treatment with BRCA mutations.

Opportunities

  • NXP002 could expand to other fibrosing interstitial lung diseases (ILDs) beyond IPF.
  • NXP001 has potential for broader application in oncology supportive care.
  • NXP004 may target additional cancer types with BRCA mutations in the future.

Threats

  • NXP002 faces competition from existing IPF treatments in the pharmaceutical market.
  • NXP001's market is constrained by specific oncology supportive care applications.
  • NXP004's effectiveness is limited to patients with BRCA mutations, reducing market size.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.